Assembly Biosciences Net Income 2010-2024 | ASMB
Assembly Biosciences net income from 2010 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Assembly Biosciences Annual Net Income
(Millions of US $) |
| 2023 |
$-61 |
| 2022 |
$-93 |
| 2021 |
$-130 |
| 2020 |
$-62 |
| 2019 |
$-98 |
| 2018 |
$-91 |
| 2017 |
$-43 |
| 2016 |
$-44 |
| 2015 |
$-28 |
| 2014 |
$-24 |
| 2013 |
$-19 |
| 2012 |
$-25 |
| 2011 |
$-34 |
| 2010 |
$-15 |
| 2009 |
$-5 |
Assembly Biosciences Quarterly Net Income
(Millions of US $) |
| 2024-06-30 |
$-11 |
| 2024-03-31 |
$-9 |
| 2023-12-31 |
$-11 |
| 2023-09-30 |
$-14 |
| 2023-06-30 |
$-17 |
| 2023-03-31 |
$-19 |
| 2022-12-31 |
$-22 |
| 2022-09-30 |
$-23 |
| 2022-06-30 |
$-24 |
| 2022-03-31 |
$-23 |
| 2021-12-31 |
$-60 |
| 2021-09-30 |
$-19 |
| 2021-06-30 |
$-24 |
| 2021-03-31 |
$-27 |
| 2020-12-31 |
$-39 |
| 2020-09-30 |
$-3 |
| 2020-06-30 |
$7 |
| 2020-03-31 |
$-27 |
| 2019-12-31 |
$-27 |
| 2019-09-30 |
$-25 |
| 2019-06-30 |
$-19 |
| 2019-03-31 |
$-27 |
| 2018-12-31 |
$-26 |
| 2018-09-30 |
$-22 |
| 2018-06-30 |
$-27 |
| 2018-03-31 |
$-16 |
| 2017-12-31 |
$-3 |
| 2017-09-30 |
$-12 |
| 2017-06-30 |
$-14 |
| 2017-03-31 |
$-14 |
| 2016-12-31 |
$-12 |
| 2016-09-30 |
$-12 |
| 2016-06-30 |
$-10 |
| 2016-03-31 |
$-11 |
| 2015-12-31 |
$-8 |
| 2015-09-30 |
$-7 |
| 2015-06-30 |
$-7 |
| 2015-03-31 |
$-7 |
| 2014-12-31 |
$-6 |
| 2014-09-30 |
$-11 |
| 2014-06-30 |
$-2 |
| 2014-03-31 |
$-4 |
| 2013-12-31 |
$-6 |
| 2013-09-30 |
$-5 |
| 2013-06-30 |
$-5 |
| 2013-03-31 |
$-4 |
| 2012-12-31 |
$-4 |
| 2012-09-30 |
$-5 |
| 2012-06-30 |
$-7 |
| 2012-03-31 |
$-8 |
| 2011-12-31 |
$-19 |
| 2011-09-30 |
$-6 |
| 2011-06-30 |
$-7 |
| 2011-03-31 |
$-3 |
| 2010-12-31 |
$-10 |
| 2010-09-30 |
$-2 |
| 2010-06-30 |
$-2 |
| 2010-03-31 |
$-2 |
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.107B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
